### 2.2.1	In vitro / physico-chemical Data

A literature search was performed to collect available information on physiochemical properties of dapagliflozin. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value**                    | Source                                                       | **Description**                                 |
| :-------------- | -------- | ---------------------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 747.95                       |                                                              | Molecular weight                                |
| pK<sub>a</sub>  |          | 8.99 (base)                  | [McFarland 1997](# 5 References)                             | Acid dissociation constant                      |
| Solubility (pH) | mg/L     | 12170 (2.4)                  | [Salem 2003](# 5 References)                                 | Solubility                                      |
| logP            |          | 2.3                          | [Lappin 2011](#5 References)                                 | Partition coefficient between octanol and water |
| fu              | %        | 28.0, 30.0,  40.0            | [Davey 1991](#5 References) , [Chu 1993a](#5 References), [Noreddin 2002](#5 References) | Fraction unbound in plasma                      |
| CYP3A4 Km       | µmol/L   | 48.7                         | [Rodrigues 1997](#5 References)                              | Michaelis-Menten constant                       |
| CLren           | mL/min   | 110-213                      | [Rodvold 1999](#5 References)                                | Renal plasma clearance                          |
| CYP3A4 Ki       | µmol/L   | 2.25, 4.12, 5.49, 29.5, 39.2 | [Polasek 2006](#5 References), [Jones 2007](#5 References), [Mayhew 2000](#5 References), [Ito 2003](#5 References) | Conc. for half-maximal inactivation             |
| CYP3A4 kinact   | 1/min    | 0.04, 0.05, 0.07, 0.23       | [Polasek 2006](#5 References), [Jones 2007](#5 References), [Mayhew 2000](#5 References), [Ito 2003](#5 References) | Maximum inactivation rate                       |
| P-gp Ki         | µmol/L   | 4.1                          | [Eberl 2007](#5 References)                                  | Conc. for half-maximal inhibition               |

### 2.2.2	Clinical Data

A literature search was performed to collect available clinical data on clarithromycin in healthy adults.

#### 2.2.2.1	Model Building

The following studies were used for model building (training data):

| Publication                | Arm / Treatment / Information used for model building        |
| :------------------------- | :----------------------------------------------------------- |
| [Chu 1992a](#5 References) | Healthy subjects with intravenous administration (0.75 h) of 250 mg |
| [Chu 1993](#5 References)  | Healthy subjects with oral administration of 250 or 500 mg as single or twice daily for 5 days |

#### 2.2.2.2	Model Verification

The following studies were used for model verification:

| Publication                         | Arm / Treatment / Information used for model building        |
| :---------------------------------- | :----------------------------------------------------------- |
| [Chu 1992](#5 References)           | Healthy Subjects with single doses between 100-1200 mg       |
| [Kees 1995](#5 References)          | Healthy subjects with oral administration of 250 or 500 mg as single or multiple dose |
| [Rengelshausen 2003](#5 References) | Oral administration of 250 mg twice a day for 1.5 days       |
| [Abduljialil 2009](#5 References)   | Oral administration of 500 mg twice a day for 3.5 days       |

